AssetMark Inc’s LENZ Therapeutics LENZ Stock Holding History

AssetMark Inc’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21	Closed	-$540	–	3135
2025 Q1	$540	Buy	+21	New	+$517	﹤0.01%	2403

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AssetMark Inc's LENZ Position: Q2 2025 in Review

AssetMark Inc sold out of LENZ Therapeutics (LENZ) in Q2 2025, closing a stake of 21 shares — an estimated $540 sold.

AssetMark Inc first reported a position in LENZ in Q1 2025 and held it in 1 quarter. The position peaked at $540 in Q1 2025. 113 funds tracked by Wall St. Rank hold LENZ as of Q2 2025.

AssetMark Inc reported no remaining LENZ Therapeutics position as of Q2 2025 after selling out during the quarter.
AssetMark Inc sold 21 LENZ Therapeutics shares in Q2 2025, an estimated $540.
AssetMark Inc first reported a position in LENZ Therapeutics in Q1 2025 and held it in 1 quarter.
AssetMark Inc's LENZ Therapeutics position peaked at $540 in Q1 2025.
113 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2025.

Based on AssetMark Inc's 13F filing for Q2 2025, filed 4 Aug 2025.